CJC-1295 research guide for Vignate. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
The hunt for CJC-1295 in Vignate almost always leads to the same conclusion: research peptides are supplied via specialist online vendors, not local pharmacies. This matters because CJC-1295 quality differs enormously across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor controls every quality variable. A legitimate CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. This guide gives Vignate researchers the methodology to evaluate CJC-1295 vendors systematically and source research-grade CJC-1295 with confidence.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Vignate researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Vetting CJC-1295 vendors begins with the COA: request the batch-specific certificate before purchasing, not after. The HPLC chromatogram is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be 98% or higher. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that do not include endotoxin results. For Vignate researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Vignate
COA-verified · International tracking · Research grade
All use of CJC-1295 in Vignate or anywhere constitutes research use — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Proper handling of CJC-1295 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger severe inflammatory responses at minute levels, and no discount compensates for this missing data. PubMed and related preprint servers provide the most complete literature coverage for CJC-1295 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
